Richards EJ, Elgin SCR: Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. Cell. 2002, 108: 489-500. 10.1016/S0092-8674(02)00644-X.
Article
CAS
PubMed
Google Scholar
Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001, 1: 194-202. 10.1038/35106079.
Article
CAS
PubMed
Google Scholar
Xu WS, Parmigiani RB, Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007, 26: 5541-5552. 10.1038/sj.onc.1210620.
Article
CAS
PubMed
Google Scholar
de Ruijter AJM, van Gennip AH, Caron HN, Kemp S, van Kuilenburg ABP: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003, 370: 737-749. 10.1042/BJ20021321.
Article
CAS
PubMed
PubMed Central
Google Scholar
Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A: Histone acetylation and disease. Cell Mol Life Sci. 2001, 58: 728-736. 10.1007/PL00000896.
Article
CAS
PubMed
Google Scholar
Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002, 3: 415-428. 10.1038/nrg962.
Article
CAS
PubMed
Google Scholar
Miller TA, Witter DJ, Belvedere S: Histone deacetylase inhibitors. J Med Chem. 2003, 46: 5097-5116. 10.1021/jm0303094.
Article
CAS
PubMed
Google Scholar
Yoshida M, Matsuyama A, Komatsu Y, Nishino N: From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem. 2003, 10: 2351-2358. 10.2174/0929867033456602.
Article
CAS
PubMed
Google Scholar
Marks PA, Breslow R: Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007, 25: 84-90. 10.1038/nbt1272.
Article
CAS
PubMed
Google Scholar
Minucci S, Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006, 6: 38-51. 10.1038/nrc1779.
Article
CAS
PubMed
Google Scholar
Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006, 5: 769-784. 10.1038/nrd2133.
Article
CAS
PubMed
Google Scholar
Duvic M, Vu J: Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2007, 16: 1111-1120. 10.1517/13543784.16.7.1111.
Article
CAS
PubMed
Google Scholar
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57: 43-66. 10.3322/canjclin.57.1.43.
Article
PubMed
Google Scholar
Wadler S: Molecular targeting in pancreatic cancer. Rev Recent Clin Trials. 2007, 2: 69-75. 10.2174/157488707779318152.
Article
CAS
PubMed
Google Scholar
Arlt A, Gehrz A, Müerköster S, Vorndamm J, Kruse M, Fölsch UR, Schäfer H: Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 2003, 22: 3243-3251. 10.1038/sj.onc.1206390.
Article
CAS
PubMed
Google Scholar
Müerköster S, Wegehenkel K, Arlt A, Witt M, Sipos B, Kruse M, Sebens T, Klöppel G, Kalthoff H, Fölsch UR, Schäfer H: Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res. 2004, 64: 1331-1337. 10.1158/0008-5472.CAN-03-1860.
Article
PubMed
Google Scholar
Ghosh S, May MJ, Kopp EB: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998, 16: 225-260. 10.1146/annurev.immunol.16.1.225.
Article
CAS
PubMed
Google Scholar
Weichert W, Boehm M, Gekeler V, Bahra M, Langrehr J, Neuhaus P, Denkert C, Imre G, Weller C, Hofmann H, Niesporek S, Jacob J, Dietel M, Scheidereit C, Kristiansen G: High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer. 2007, 97: 523-530. 10.1038/sj.bjc.6603878.
Article
CAS
PubMed
PubMed Central
Google Scholar
Karin M, Cao Y, Greten FR, Li Z: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002, 2: 301-310. 10.1038/nrc780.
Article
CAS
PubMed
Google Scholar
Hu J, Colburn NH: Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. Mol Cancer Res. 2005, 3: 100-109. 10.1158/1541-7786.MCR-04-0070.
Article
CAS
PubMed
Google Scholar
Lüttges J, Schemm S, Vogel I, Hedderich J, Kremer B, Klöppel G: The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol. 2000, 191: 154-161. 10.1002/(SICI)1096-9896(200006)191:2<154::AID-PATH603>3.0.CO;2-C.
Article
PubMed
Google Scholar
Weichert W, Röske A, Gekeler V, Beckers T, Ebert MPA, Pross M, Dietel M, Denkert C, Röcken C: Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008, 9: 139-148. 10.1016/S1470-2045(08)70004-4.
Article
CAS
PubMed
Google Scholar
Wilson AJ, Byun D, Popova N, Murray LB, L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM: Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem. 2006, 281: 13548-13558. 10.1074/jbc.M510023200.
Article
CAS
PubMed
Google Scholar
Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, Raju GC, Hooi SC: Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 2005, 12: 395-404. 10.1038/sj.cdd.4401567.
Article
CAS
PubMed
Google Scholar
Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, Kristiansen G: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008, 98: 604-610. 10.1038/sj.bjc.6604199.
Article
CAS
PubMed
PubMed Central
Google Scholar
Weichert W, Röske A, Niesporek S, Noske A, Buckendahl A, Dietel M, Gekeler V, Boehm M, Beckers T, Denkert C: Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res. 2008, 14: 1669-1677. 10.1158/1078-0432.CCR-07-0990.
Article
CAS
PubMed
Google Scholar
Miyake K, Yoshizumi T, Imura S, Sugimoto K, Batmunkh E, Kanemura H, Morine Y, Shimada M: Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas. 2008, 36: e1-9. 10.1097/MPA.0b013e31815f2c2a.
Article
CAS
PubMed
Google Scholar
Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB: Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem. 2006, 281: 5612-5622. 10.1074/jbc.M507213200.
Article
CAS
PubMed
Google Scholar
Imre G, Gekeler V, Leja A, Beckers T, Boehm M: Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res. 2006, 66: 5409-5418. 10.1158/0008-5472.CAN-05-4225.
Article
CAS
PubMed
Google Scholar
Chen LF, Fischle W, Verdin E, Greene WC: Duration of nuclear NF-κB action regulated by reversible acetylation. Science. 2001, 293: 1653-1557. 10.1126/science.1062374.
Article
CAS
Google Scholar
Göttlicher M, Minucci S, Zhu P, Krämer O, Schimpf A, Giavara S, Sleeman J, Lo Coco F, Nervi C, Pelicci PG, Heinzel T: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20: 6969-6978. 10.1093/emboj/20.24.6969.
Article
PubMed
PubMed Central
Google Scholar
Farrow B, Sugiyama Y, Chen A, Uffort E, Nealon W, Mark Evers B: Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg. 2004, 239: 763-9. 10.1097/01.sla.0000128681.76786.07. discussion 769-71.
Article
PubMed
PubMed Central
Google Scholar
Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, Tsao M, Evans DB, Abbruzzese JL, McDonnell TJ, Chiao PJ: The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene. 2002, 21: 6510-6519. 10.1038/sj.onc.1205848.
Article
CAS
PubMed
Google Scholar